Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GuiErBai (GEB) is a traditional Chinese medicine (Miao nationality) compound preparation developed for the treatment of cervical cancer. It is composed of extracts from *Podophyllum* (the rhizome of *Dysosma versipellis*), *Dictamnus dasycarps*, and *Angelica dahurica*. The primary active chemical constituents of GuiErBai include podophyllotoxin (PTOX), imperatorin, isoimperatorin, and *Angelica dahurica* alkaloids. GuiErBai exhibits robust anti-tumor activity against cervical cancer both in vitro and in vivo by inducing cell cycle arrest at the G2/M phase, promoting apoptosis, and triggering autophagy in tumor cells. It also elevates reactive oxygen species (ROS) levels and mitochondrial membrane potential, while downregulating the expression of CD34, VEGF, and caspase-3 in tumor tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GuiErBai.